发布时间：2025-10-20 14:07 New safety, efficacy and pharmacokinetic results presented from dose escalation portion of the study

Anti-tumour activity observed across all dose levels and in various tumour indications



NEWCASTLE, England--(BUSINESS WIRE)--Iksuda Therapeutics (Iksuda), the developer of class leading, antibody drug conjugates (ADCs), today announces the presentation of new data from its Phase 1 study of IKS014, a human epidermal growth factor receptor 2 (HER2)-directed ADC, in patients with advanced HER2+ solid tumours. The data was presented at the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany.

The Phase 1 study (NCT05872295) is a non-randomised, open-label, multicentre trial evaluating IKS014 in patients with locally advanced or metastatic solid tumours that express HER2. Part I, the dose escalation portion, is being conducted in sites in Australia and is designed to establish the maximum tolerated dose (MTD) and/o
=*=*=*=*=*=
当前为第1/6页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页